Abstract
Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.
| Original language | English |
|---|---|
| Pages (from-to) | 81-92 |
| Number of pages | 12 |
| Journal | Journal of Medicine |
| Volume | 23 |
| Issue number | 2 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease. / Fabris, F.; Steffan, A.; Randi, M. L.; Avruscio, G.; Cordiano, I.; Girolami, A.
In: Journal of Medicine, Vol. 23, No. 2, 1992, p. 81-92.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease
AU - Fabris, F.
AU - Steffan, A.
AU - Randi, M. L.
AU - Avruscio, G.
AU - Cordiano, I.
AU - Girolami, A.
PY - 1992
Y1 - 1992
N2 - Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.
AB - Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.
UR - http://www.scopus.com/inward/record.url?scp=0026713064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026713064&partnerID=8YFLogxK
M3 - Article
C2 - 1512524
AN - SCOPUS:0026713064
VL - 23
SP - 81
EP - 92
JO - Journal of Medicine
JF - Journal of Medicine
SN - 0025-7850
IS - 2
ER -